Obesity drug semaglutide tested for brain benefits in new trial
Disease control
Not yet recruiting
This phase 4 trial will study 240 adults aged 35-55 with class I/II obesity to see if weight loss from semaglutide (Ozempic/Wegovy) improves brain health. Participants will take the drug weekly for 80 weeks and undergo MRI scans, cognitive tests, and blood work. The study also in…
Phase: PHASE4 • Sponsor: Alain Dagher • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC